Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

ICON releases its ICON Cares 2024 Report
ICON releases its ICON Cares 2024 Report


ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today releases its ICON Cares 2024 Report. The report outlines how the company is

Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend
Chemed Corporation Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend


Stockholders of Chemed Corporation (NYSE: CHE) today elected a slate of nine directors at the Company’s 2025 annual stockholders’ meeting.



Stockholders ratified the continuation of

EQS-News: Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
EQS-News: Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
EQS-News: Formycon and Fresenius Kabi announce FDA Approval of Interchangeability for FYB202/Otulfi® (ustekinumab-aauz)
Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025
Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025


Savara Inc. (Nasdaq: SVRA) (the Company), a clinical-stage biopharmaceutical company focused on rare respiratory diseases, today announced new data in two poster presentations at the ATS

STAAR Surgical Announces $30 Million Share Repurchase Authorization
STAAR Surgical Announces $30 Million Share Repurchase Authorization


STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of

Agilent to Participate in Jefferies Global Healthcare ConferencePhoto, wide shot, wide-angle lens,  Biotech company, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Sebastião Salgado: https://img.theapi.app/temp/80e18bfd-1ff8-4487-af62-1cdb7de1ceb6.png
Agilent to Participate in Jefferies Global Healthcare Conference


Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell — along with CFO Bob McMahon — will participate in a fireside chat at the Jefferies Global Healthcare Conference at

Premier Announces the Nation’s 15 Top Health Systems®
Premier Announces the Nation’s 15 Top Health Systems®


Premier, Inc. (NASDAQ: PINC) today announced the nation’s 15 Top Health Systems®.



Premier’s 15 Top Health Systems® annual study is the only study that includes a comprehensive analysis of the

LivaNova to Present at the Jefferies Global Healthcare Conference
LivaNova to Present at the Jefferies Global Healthcare Conference


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global

Simulations Plus Releases DILIsym® 11
Simulations Plus Releases DILIsym® 11


Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical

EQS-Adhoc: MAQUET Medical Systems AG submits squeeze-out request to Pulsion Medical Systems SE
EQS-Adhoc: MAQUET Medical Systems AG submits squeeze-out request to Pulsion Medical Systems SE
EQS-Adhoc: MAQUET Medical Systems AG submits squeeze-out request to Pulsion Medical Systems SE
EQS-News: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board
EQS-News: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board
EQS-News: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
Lonza Appoints Andreas Bohrer as Chief Legal & Corporate Affairs Officer
Chemed Corporation to Present at the 2025 RBC Global Healthcare Conference
Chemed Corporation to Present at the 2025 RBC Global Healthcare Conference


Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the RBC Global Healthcare Conference on Wednesday, May 21, 2025, at approximately 9:30 a.m. (ET) at The

EQS-News: Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
EQS-News: Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
EQS-News: Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
Savara Reports First Quarter 2025 Financial Results and Provides a Business Update
Savara Reports First Quarter 2025 Financial Results and Provides a Business Update


Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2025 and

GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025
GenSight Biologics Announces Approval of All Resolutions Supported by the Board of Directors at the Combined General Meeting of May 13, 2025


Regulatory News:



The Combined General Meeting of shareholders of GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and

Charles River Laboratories to Present at Bank of America Health Care Conference
Charles River Laboratories to Present at Bank of America Health Care Conference


Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Bank of America 2025 Health Care Conference on Wednesday, May 14th, at 8:40 a.m. PT (11:40

Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions
Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss

Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update
Poxel Reports Consolidated Revenue for the First Quarter 2025 and Provides Corporate Update


Regulatory News:



POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

EQS-News: Eckert & Ziegler Starts with Earnings Growth in Q1 2025 and Confirms Full-Year Forecast
EQS-News: Eckert & Ziegler Starts with Earnings Growth in Q1 2025 and Confirms Full-Year Forecast
EQS-News: Eckert & Ziegler Starts with Earnings Growth in Q1 2025 and Confirms Full-Year Forecast
Sonova publishes Annual Report 2024/25
Sonova publishes Annual Report 2024/25
Sonova publishes Annual Report 2024/25
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial Results


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2025 financial results.



“This quarter we continued to advance

Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering


Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded

Acadia Healthcare Reports First Quarter 2025 Results
Acadia Healthcare Reports First Quarter 2025 Results


Acadia Healthcare Company, Inc. (“Acadia” or the “Company”) (NASDAQ: ACHC) today announced financial results for the first quarter ended March 31, 2025.



First Quarter 2025 Highlights




  • Revenue

Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference
Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference


Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced members of the management team will host 1x1 meetings and